Paper Details

  1. Home
  2. Paper Details

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.

Author: ArancioF, ArmuzziA, CammarotaG, CannizzaroO, CianciR, CuocoL, GasbarriniA, GasbarriniG, PirozziG, SantarelliL, ZoccoM A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Two 1-week rabeprazole-based triple therapies including levofloxacin effectively eradicated Helicobacter pylori. The regimens were safe and well-tolerated, achieving eradication rates of 92% (RLA) and 90% (RLT). This suggests that levofloxacin may be a viable alternative to clarithromycin in triple therapy regimens.
Paper Details　
Original Abstract of the Article :
BACKGROUND: One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM: To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2000.00846.x

データ提供：米国国立医学図書館（NLM）

One-Week Triple Therapies for Helicobacter pylori Infection: Effective and Well-Tolerated

This research, like a camel traversing the vast desert of gastrointestinal medicine, explores the efficacy of one-week triple therapies for eradicating Helicobacter pylori infection. The researchers investigated the effectiveness of two regimens, both containing rabeprazole and levofloxacin. The study found that both regimens achieved high eradication rates and were well-tolerated by patients.

One-Week Triple Therapies: A Convenient and Effective Approach

This study, like a refreshing oasis in the desert of H. pylori treatment, demonstrates the effectiveness and convenience of one-week triple therapies for eradicating H. pylori infection. The findings highlight the potential of levofloxacin as an alternative to clarithromycin in triple therapy regimens.

Managing H. pylori Infection: A Multifaceted Approach

The study emphasizes the importance of individualized treatment approaches for H. pylori infection, considering patient factors and the potential for antibiotic resistance. It's essential to discuss treatment options with your healthcare provider to ensure the best possible outcomes.

Dr.Camel's Conclusion

This research provides valuable insights into the effectiveness and tolerability of one-week triple therapies for H. pylori infection. It offers a promising approach for eradicating this common infection, highlighting the importance of ongoing research to optimize treatment strategies.

Date :
  1. Date Completed 2000-11-16
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

11012480

DOI: Digital Object Identifier

10.1046/j.1365-2036.2000.00846.x

Related Literature

Article Analysis
・Side Effects of rabeprazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.